Decoy Therapeutics awards director 2,000 shares
Director Paul Lammers received 2,000 restricted shares of Decoy Therapeutics common stock vesting in full on August 30, 2027.
Rhea-AI Filing Summary
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Lammers Paul reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) reported that director Paul Lammers received a grant of 2,000 shares of Common Stock as restricted stock under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan on August 31, 2026. The grant carries a vesting schedule under which 100 percent will vest on August 30, 2027. Following this award, Lammers is reported to beneficially own 2,001 shares of Decoy Therapeutics common stock on a direct basis, with this post-transaction amount adjusted to reflect reverse stock splits that became effective on August 15, 2025 and March 6, 2026. No Rule 10b5-1 trading plan is reported for this transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 2,000 shares
Grant/Award
1 txn
Insider
Lammers Paul
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1, F2 | 2,000 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 2,001 shares (Direct)
Footnotes (2)
- F1. Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
- F2. Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.
Key Figures
Restricted stock grant: 2,000 shares
Price per share for award: $0.00 per share
Shares beneficially owned after transaction: 2,001 shares
+3 more
6 metrics
Restricted stock grant
2,000 shares
Common Stock awarded to director Paul Lammers on August 31, 2026
Price per share for award
$0.00 per share
Reported transaction price for the 2,000-share restricted stock grant
Shares beneficially owned after transaction
2,001 shares
Direct holdings of Paul Lammers after the restricted stock grant
Vesting date of restricted stock
August 30, 2027
Date when 100 percent of the 2,000 restricted shares will vest
Reverse stock split effective date
August 15, 2025
One of two reverse stock splits reflected in the adjusted share count
Reverse stock split effective date
March 6, 2026
Second reverse stock split reflected in the adjusted share count
Key Terms
Restricted stock, Equity Incentive Plan, reverse stock splits
3 terms
Restricted stock financial
"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Equity Incentive Plan financial
"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
reverse stock splits financial
"adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026"
A reverse stock split is when a company combines multiple existing shares into fewer higher-priced shares—like trading four small slices of a pie for one larger slice. It doesn’t change the overall value of an investor’s holdings immediately, but it raises the per-share price and can matter to investors because it can affect market perception, stock exchange listing eligibility, and trading liquidity, and it changes share counts used in investor metrics.
FAQ
What transaction did Decoy Therapeutics (DCOY) disclose for director Paul Lammers?
Decoy Therapeutics disclosed that director Paul Lammers received a grant of 2,000 shares of restricted Common Stock on August 31, 2026 under the company’s 2026 Equity Incentive Plan, reported as a grant or award acquisition rather than an open-market purchase.
Was the Decoy Therapeutics (DCOY) Form 4 transaction made under a Rule 10b5-1 trading plan?
The Form 4 indicates the document-level Rule 10b5-1 checkbox is not checked, and there is no footnote stating that the grant was made under a Rule 10b5-1 trading plan, so no Rule 10b5-1 plan is reported for this transaction.
What role did the Decoy Therapeutics 2026 Equity Incentive Plan play in the DCOY Form 4 grant?
The reported grant of 2,000 shares to Paul Lammers is described as restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, indicating the award is part of the company’s equity-based compensation program for eligible participants such as directors.
How were prior Decoy Therapeutics (DCOY) reverse stock splits reflected in Paul Lammers’ share count?
A footnote states that shares beneficially owned by Paul Lammers after the transaction were adjusted to reflect reverse stock splits effective on August 15, 2025 and March 6, 2026, so his post-transaction 2,001-share figure is split-adjusted.
AI-generated analysis. How Rhea-AI works. Not financial advice.
